ReviewOncology and therapy2026

Repurposing Resmetirom to Suppress MASLD/MASH-HCC in the Dysmetabolic Era.

Amedeo Lonardo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.